

Correction: Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines

In this article (*Cancer Epidemiol Biomarkers Prev* 2013;22:146–9), which was published in the January 2013 issue of *Cancer Epidemiology, Biomarkers & Prevention* (1), the development study for the Tyrer-Cuzick model was incorrectly identified as the Mayo Clinic Benign Breast Disease cohort in the Introduction. The model is correctly identified below. The authors regret the error.

The model is a statistical model based in part on the data obtained from the International Breast Intervention Study (IBIS).

Reference

1. Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. *Cancer Epidemiol Biomarkers Prev* 2013;22:146–9.

Published OnlineFirst May 16, 2013.

doi: 10.1158/1055-9965.EPI-13-0300

©2013 American Association for Cancer Research.